Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Vernalis
Icagen Pfenex |
| gptkbp:businessModel |
drug discovery
drug development |
| gptkbp:CEO |
gptkb:John_Higgins
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
pharmaceutical licensing
royalty-based business |
| gptkbp:founded |
1987
|
| gptkbp:founder |
gptkb:Brook_Byers
|
| gptkbp:hasCompany |
yes
|
| gptkbp:headquarters_location |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ligand Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Kyprolis
gptkb:Promacta Captisol |
| gptkbp:numberOfEmployees |
~50 (as of 2023)
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
LGND
|
| gptkbp:website |
https://www.ligand.com/
|
| gptkbp:bfsParent |
gptkb:Howard_Birndorf
gptkb:Neurogen gptkb:bexarotene |
| gptkbp:bfsLayer |
8
|